Home/Filings/4/0000899243-19-028027
4//SEC Filing

Siu Christine 4

Accession 0000899243-19-028027

CIK 0001731831other

Filed

Nov 21, 7:00 PM ET

Accepted

Nov 22, 9:00 PM ET

Size

18.0 KB

Accession

0000899243-19-028027

Insider Transaction Report

Form 4
Period: 2019-11-21
Siu Christine
See Remarks
Transactions
  • Exercise/Conversion

    Common Stock

    2019-11-21$0.59/sh+25,000$14,75061,470 total
  • Sale

    Common Stock

    2019-11-21$56.00/sh200$11,20036,470 total
  • Sale

    Common Stock

    2019-11-21$55.12/sh24,800$1,366,87736,670 total
  • Sale

    Common Stock

    2019-11-22$55.29/sh601$33,23236,470 total
  • Sale

    Common Stock

    2019-11-22$54.71/sh9,399$514,22437,071 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2019-11-2125,000192,191 total
    Exercise: $0.59Exp: 2027-12-21Common Stock (25,000 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2019-11-2110,000182,191 total
    Exercise: $0.59Exp: 2027-12-21Common Stock (10,000 underlying)
  • Exercise/Conversion

    Common Stock

    2019-11-22$0.59/sh+10,000$5,90046,470 total
Footnotes (4)
  • [F1]Represents the weighted average sale price of the shares sold from $55.00 to $55.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  • [F2]Represents the weighted average sale price of the shares sold from $54.21 to $55.19 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  • [F3]Represents the weighted average sale price of the shares sold from $55.21 to $55.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  • [F4]The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Issuer

Eidos Therapeutics, Inc.

CIK 0001731831

Entity typeother

Related Parties

1
  • filerCIK 0001743029

Filing Metadata

Form type
4
Filed
Nov 21, 7:00 PM ET
Accepted
Nov 22, 9:00 PM ET
Size
18.0 KB